Aspirin
Bamlanivimab
Bromhexine
Budesonide
Casirivimab/i..
Colchicine
Conv. Plasma
Curcumin
Favipiravir
Fluvoxamine
Hydroxychloro..
Iota-carragee..
Ivermectin
Melatonin
Molnupiravir
Nigella Sativa
Nitazoxanide
Povidone-Iod..
Probiotics
Proxalutamide
Quercetin
Remdesivir
Sotrovimab
Vitamin A
Vitamin C
Vitamin D
Zinc

Other
Feedback
Home
Home   COVID-19 treatment studies for Fluvoxamine  COVID-19 treatment studies for Fluvoxamine  C19 studies: Fluvoxamine  Fluvoxamine   Select treatmentSelect treatmentTreatmentsTreatments
Aspirin Molnupiravir
Bamlanivimab Nigella Sativa
Bromhexine Nitazoxanide
Budesonide Povidone-Iod..
Casirivimab/i.. Probiotics
Colchicine Proxalutamide
Conv. Plasma Quercetin
Curcumin Remdesivir
Favipiravir Sotrovimab
Fluvoxamine Vitamin A
Hydroxychloro.. Vitamin C
Iota-carragee.. Vitamin D
Ivermectin Zinc
Melatonin

Other Adoption
 
00.250.50.7511.251.51.752+Lenze (DB RCT)93%0.07 [0.00-1.28]progression0/806/72Improvement, RR [CI]TreatmentControlSeftel (QR)84%0.16 [0.01-3.29]death/ICU0/772/48Tau​2 = 0.00; I​2 = 0.0%Early treatment89%0.11 [0.01-0.85]0/1578/12089% improvementReis (DB RCT)29%0.71 [0.37-1.29]death17/73924/733Improvement, RR [CI]TreatmentControlTau​2 = 0.00; I​2 = 0.0%Late treatment29%0.71 [0.37-1.29]17/73924/73329% improvementAll studies63%0.37 [0.09-1.47]17/89632/85363% improvement3 fluvoxamine COVID-19 studiesc19fluvoxamine.com Sep 24, 2021Tau​2 = 0.65; I​2 = 35.2%; Z = 1.41Effect extraction pre-specifiedFavors fluvoxamineFavors control
Database of all fluvoxamine COVID-19 studies. Submit updates/corrections.
Aug 23
Late Reis et al., Preprint (Preprint) death, ↓29.3%, p=0.26 Effect of early treatment with fluvoxamine on risk of emergency care and hospitalization among patients with COVID-19: The Together randomized platform clinical trial
Details   Together Trial preprint showing significantly lower hospitalization/extended ER visits with treatment, per-protocol analysis RR 0.34 [0.20-0.54]; ITT analysis RR 0.71 [0.54-0.93]. Adherence was only 73.2%. Symptom onset was unspecified or..
Aug 12
Review Hoertel et al., Molecular Psychiatry, doi:10.1038/s41380-021-01254-3 (Review) (Peer Reviewed) review Repurposing antidepressants inhibiting the sphingomyelinase acid/ceramide system against COVID-19: current evidence and potential mechanisms
Details   Review of the mechanisms of action and clinical studies for the treatment of COVID-19 with FIASMA antidepressants such as fluoxetine, fluvoxamine, paroxetine, escitalopram, or amitriptyline.
Jun 29
PrEP Assanovich et al., Psychiatry, Psychotherapy and Clinical Psychology, doi:10.34883/PI.2021.12.2.007 (Peer Reviewed) Fluvoxamine in the Treatment of Patients with COVID-19
Details   Report on the use of fluvoxamine for COVID-19 noting that "patients with COVID-19 taking fluvoxamine did not report clinical complications of coronavirus infection". Only the abstract is currently available.
Apr 20
Review Sukhatme et al., Front. Pharmacol., doi:10.3389/fphar.2021.652688 (Review) (Peer Reviewed) review Fluvoxamine: A Review of Its Mechanism of Action and Its Role in COVID-19
Details   Review of mechanisms of action of fluvoxamine and other SSRIs that could be beneficial for COVID-19 treatment, including lower platelet aggregation, decreased mast cell degranulation, interference with endolysosomal viral trafficking, reg..
Mar 6
Review Kirsch, S. (Review) (Preprint) review COVID FAQ
Details   COVID FAQ from the founder of the COVID-19 Early Treatment Fund [1], including an extensive analysis of the fluvoxamine trials and other supporting evidence.
Feb 1
Early Seftel et al., Open Forum Infectious Diseases, doi:10.1093/ofid/ofab050 (Peer Reviewed) death/ICU, ↓83.9%, p=0.15 Prospective cohort of fluvoxamine for early treatment of COVID-19
Details   Prospective quasi-randomized (patient choice) study with 125 outpatients, 77 treated with fluvoxamine, showing lower death/ICU admission (0 of 77 vs. 2 of 48), lower hospitalization (0 of 77 vs. 6 of 48), and faster recovery with treatmen..
Nov 12
2020
Early Lenze et al., JAMA, doi:10.1001/jama.2020.22760 (Peer Reviewed) progression, ↓92.7%, p=0.009 Fluvoxamine vs Placebo and Clinical Deterioration in Outpatients With Symptomatic COVID-19: A Randomized Clinical Trial
Details   RCT 152 outpatients, 80 treated with fluvoxamine showing lower progression with treatment (0 of 80 versus 6 of 72 control).
Aug 17
2020
Late Hoertel et al., Molecular Psychiatry, doi:10.1038/s41380-021-01021-4 (Peer Reviewed) Association between antidepressant use and reduced risk of intubation or death in hospitalized patients with COVID-19: results from an observational study
Details   Retrospective 7,230 hospitalized COVID-19 patients in France, 345 receiving an antidepressant medication within 48 hours of admission. There was a significant association between antidepressant use and reduced risk of intubation or death ..
Please send us corrections, updates, or comments. Vaccines and treatments are both extremely valuable and complementary. All practical, effective, and safe means should be used. Elimination of COVID-19 is a race against viral evolution. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. Denying the efficacy of any method increases the risk of COVID-19 becoming endemic; and increases mortality, morbidity, and collateral damage. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. Treatment protocols for physicians are available from the FLCCC.
  or use drag and drop   
Thanks for your feedback! Please search before submitting papers and note that studies are listed under the date they were first available, which may be the date of an earlier preprint.
Submit